LifeSci Capital downgraded Centessa (CNTA) to Market Perform from Outperform after Eli Lilly (LLY) announced an agreement to acquire the company for $38 per share in cash plus a non-transferable contingent value right worth up to $9 per share.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNTA:
- Centessa downgraded to Market Perform from Outperform at Leerink
- Eli Lilly to Acquire Centessa Pharmaceuticals in Cash Deal
- Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
- Alkermes jumps 15% on renewed biotech M&A buzz, says Leerink
- Centessa acquisition ‘may help rouse’ Alkermes shares, says RBC Capital